Sidekick Health announced an integrated digital therapeutics solution in conjunction with pharmaceutical company Eli Lilly and Company for patients battling breast cancer. The collaboration will mark the first phase of Sidekick and Lilly's relationship. The integrated digital therapeutics offering will be initially rolled out in Germany where, according to the World Health Organization, there were 69,697 new cases of breast cancer in 2020, representing 24.5% of all cancers affecting females that year, and 11.1% of cancers affecting all sexes.

This further expansion of Sidekick's portfolio to treat breast cancer will be tailored to support the needs of patients Through Sidekick's unique platform, patients will be given access to a tailored digital treatment plan that engages in health-improving tasks, which promote behavior modification and overcome barriers to change. Sidekick's solution focuses on five main areas: physical activity, tailored diet, sleep, stress management, and medication adherence, the latter representing a significant obstacle to recovery in patients undergoing cancer treatment. Patients will also be given access to educational content that has been created in close collaboration with clinical experts and patient advocacy groups, helping to provide them with unique insights into living with cancer.

The launch of this digital solution for breast cancer patients in Germany, as well as patients on a branded Lilly medication, is being scheduled for July of this year. Next steps for collaboration are being considered, including other international markets.